Inactive Instrument

Other languages Profound Medical Corp Toronto S.E.

Equities

PRN

CA74319B1067

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

May. 06	Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	MT
May. 06	Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	Mar. 07
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	Feb. 27
Profound Medical Up 1.9% In US After Hours As Announces Non-Brokered Private Placement	Jan. 16
Sector Update: Health Care Stocks Steady Premarket Thursday	Dec. 28
Wall Street in Consolidation Mode in Penultimate Session for 2023, Driving Muted Premarket Action for US Equity Futures	Dec. 28
Profound Medical Prices $20 Million Public Share Offering	Dec. 28
Profound Medical Plans Stock Offering; Shares Drop After-Hours	Dec. 27
Profound Medical Announces CMS Extension of Temporary 'Code' for Tulsa to ASC Setting	Nov. 03
Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting	Nov. 03
Profound Medical Reports Q3 2023 Revenue of US$1.7 Million	Nov. 02
Profound Medical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Profound Medical Gets FDA Clearance for Tulsa-Pro Thermal Boost	23-09-25
Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost	23-09-25
Profound Medical Plans At-the-Market Offering of up to US$30 Million; Up Nearly 5%	23-09-07
Profound Medical Approves At-the-Market Offering of Up to $30 Million of Common Stock	23-09-07
Profound Medical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Profound Medical Reports Q2 Net Loss of US$7.4 Million	23-08-09
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases	23-06-02
Profound Medical Reports Q1 2023 Results, Provides Operations Update	23-05-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Profound Medical Corp Toronto S.E.

Equities

PRN

CA74319B1067

Other languages

Filters